Redbiotec was founded in 2006 as an ETH spin-off. Having sold its CMV vaccine business to Pfizer in 2015, Redbiotec has since developed potent HSV-2 immunotherapies, and a platform technology of engineered bacteria - BRISPR® - to deliver therapeutic cargos of various nature for the treatment of cancer and genetic disorders.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2006
  • Number of employees in Switzerland
    10-19
Key business